ISO ISMPOCON 2025, Jaipur				
"Winning the Battle Against Cancer- From Insights to Impact!" Friday - Day 1 - 31st October 2025 Hall A - RL Swarnakar Auditorium				
			08:00 AM onwards	Registration
			08:00 AM - 09:00 AM	Meet the Professor
08:55 AM - 09:00 AM	Opening remarks and welcome - Dr. Hemant Malhotra			
00.00 ANA 10.20 ANA	Session 1 : Breast Cancer			
09:00 AM - 10:30 AM Chairpersons	Session 1 : Breast Cancer			
Chairpersons				
	KEYNOTE LECTURE 01- Breast Cancer: In The Era of Multiple Published Guidelines, Is MTD Still			
09:00 AM - 09:20 AM	Needed?			
Speaker				
09:20 AM - 09:30 AM	Recent Practice Changing Landmark Papers			
09:20 AM - 09:25 AM	VENUS trial - can we avoid SLNB in carefully selected node negative breast cancer patients?			
Speaker	SO			
эрсиксі				
00.25 484 00.20 484	DESTINY breast 09 (DB09) trial -Trastuzumab deruxtecan (T-DXd) ± pertuzumab as a first-line Rx			
09:25 AM - 09:30 AM	for HER2-+ve MBC			
Speaker	МО			
22.22.11.22.52.11.				
09:30 AM - 09:50 AM	DEBATE 01: Early stage TNBC -are we looking at 'No Surgery' in future?			
10 min (8+2) - Debater (Yes) 10 min (8+2) - Debater (No)				
10 mm (0+2) Debater (140)				
09:50 AM - 10:10 AM	Adjuvant therapy for High Risk Hormone receptor Positive EBC			
Speaker				
10:10 AM - 10:40 AM	Panel discussion 01 - Two Cases			
	1- BRCA positive high risk breast cancer patient			
	2- HR +ve, HER 2 -ve high risk breast cancer patient			
Moderator	3- Locally advanced breast cancer in a 80 year years old female TBA			
Panelist	MO2,SO2, RO2, Oncopath1,			
	- / / - / /			
10:40 AM - 11:00 AM	Panel discussion 02 - Identifying patients with HR+ HER2- Early breast cancer at high risk of			
	recurrence			
Moderator	TBA			
Panelist	TBA			
11:00 AM - 12.00 PM	Session 2 : Head & Neck			
Chairpersons	Jession 2. Head & Neck			
5.7411 per 50110				
11:00 AM - 11.20 AM	KEYNOTE LECTURE 02: Innovative Solutions in head and neck cancers - India's No-1 Cancer			
Speaker				

Recent Practice Changing Landmark Papers

11:20 AM - 11.30 AM

	IVEVNIOTE COO trial. Degian agative Immunath are not in Legally, advanced 119 N. sevenages call
11:20 AM - 11.25 AM	KEYNOTE-689 trial - Perioperative Immunotherapy in Locally advanced H&N squamoos cell
Speaker	Carcinoma MO
Speaker	
11:25 AM - 11.25 AM	UPGrade RT- Clinical benefit & safety of definitive RT with reduced v/s standard elective dose
Speaker	RO
эрсиксі	
	PANEL DISCUSSION 03: Locally advanced HNSCC -
11:10 AM - 11.40 AM	1. Recurrent Head & Neck Cancer
	2. Locally Advanced CA Buccal Mucosa
Moderator	2. Edeally Advanced CA Buccar Wideosa
Panelists	
11:40 AM - 12.00 PM	DEBATE 02 - Early stage T1/T2 oropharynx should be treated with curative RT (SBRT v/s TORS)
	RO
10 min (8+2) - Debater (No)	
, ,	
12:00 PM - 12.20 PM	Sponsored Talk
Speaker	
12:20 PM - 12:30 PM	Tea-Coffee Break
12:30 PM - 12:50 PM	Keynote Lecture 3 : Electronic data keeping in Oncology
Speaker	
12:50 PM - 01:45 PM	Session 3 : Precision Oncology
Chairpersons	
12:50 PM - 01:05 PM	Keynote Lecture 04 : Advances in Molecular Oncology (CtDNA)"
Speaker	
01:05 PM - 01:25 PM	DEBATE 03: Genomic profiling in today's oncology practice – Should be done in all patients at
01.03 1 101 01.23 1 101	diagnosis?
Debater (Yes) (10 min)	
Debater (No) (10 min)	
	MOLECULAR CASE BASED PANEL DISCUSSION 04 :
01:25 PM - 01:45 PM	Case 1- NSCLC with complex mutations
	Case 2- Thyroid Cancer
	Case 3 - GBM
Moderator	
Panelists	
04.45.044.02.04.044	
01:45 PM - 02:30 PM	Lunch Break
2:30 PM - 3:30 PM	HER2 + in Solid Tumors (Supported by Astrazeneca)
2.30 FIVI - 3.30 FIVI	
2:30 PM - 2:45 PM	Newer paradigms in the management of HER2+ Solid Tumors
Speaker	prewer paradigms in the management of fields solid fullions
эрсаксі	
	Panel Discussion 05 - on Management of HER2+ solid tumors in the current era
	Case-1: HER2+ Gastric Cancer,
2:45 PM - 3:25PM	Case-2: HER2+ Endometrial Cancer,
Moderator	Case-3: HER2+ Biliary Tract Cancer,
iviouerator	

Panelists	
3:25 PM - 3:30 PM	Summary & Expert Comments
3:30 PM - 5:00 PM	
3.30 1 101 3.00 1 101	
3:30 PM - 3:50 PM	Sponsored Talk: Tislelizumab in Lung Cancer: Current Evidence and Future Directions
Speaker	
3:50 PM - 4:10 PM	Sponsored Talk: Next-Gen Immunotherapy: Toripalimab Impact in the mangement of different cancers
Speaker	
4:10 PM - 4:30 PM	Beyond Chemotherapy options in extensive stage SCLC
Speaker	beyond Chemotherapy options in extensive stage SCLC
1 -	
4:30 PM - 5:00 PM	Panel Discussion 06: Recently launched ICIs (Serplulimab, Toripalimab, Tislelizumab etc) - Are they as good as earlier ones?
Moderator	
Panelists	
5:00 PM - 5:30 PM	Geriatric Medicine
E:00 DN4 E:30 DN4	Comprehensive Corietrie Assessment
5:00 PM - 5:20 PM Speaker	Comprehensive Geriatric Assessment
эрсикс	
5:20 PM - 5:40 PM	Case Based Discussion 07: 80 year old female with locally advanced breast cancer
Moderator	
Panelists	MO 3 ; SO 2 ; RO 1 ; Geriatric Medicine 1 ; Pall Care 1
05:40 PM - 06:00 PM	Quiz Navigating therapry selection through Oncogenomics Maize (Open For All) Quiz Masters
06:00 PM - 07:10 PM	Symposium on NSCLC with targetable mutations
06:00 PM - 06:20 PM	Recent Strategies in the Management of ALK+ NSCLC
Speaker	
·	
06:20 PM - 06:40 PM	Receent Strategies in the Management of RET mutated NSCLC
Speaker	
06:40 PM - 07:10 PM	PANEL DISCUSSION CASE BASED 08 - ALK+ NSCLC
Moderator	
Panelists	
07:15 PM - 07:45 PM	Inauguration
07:45 PM onwards	Inaugural Dinner
07.45 PIVI UTIWATUS	maugurar Diffile